, Not , is a Risk Factor Associated with Radiotherapy Plus Chemotherapy Efficacy in Glioma

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2018 Jun 5

PMID 29861627

Citations 6

Authors

Cuilin Li

Hecun Zou

Zhifei Wang

Xinyue Tang

Xitang Fan

Ke Zhang

Jianqiu Liu

Zhi Li

Affiliations

Soon will be listed here.

Abstract

Background/aim: Repressor element silencing transcription factor () is a transcription repressor, expressed in several malignancies. This study aims to evaluate the prognostic values of and its splicing variant in glioma, and investigate the potential correlation between and .

Methods: and expression values were evaluated by qRT-PCR in 89 patients with gliomas and 10 with normal brain tissues.

Results: Upregulation of was related to higher World Health Organization (WHO) grade, larger tumor size, higher ki67, and higher p53 positive rate. After radiotherapy+temozolomide (RT+TMZ) treatment, low expression patients could get better therapeutic efficacy (=0.031). The positive rate of expression was only 13.5% in glioma tissues, and expression was not associated with clinical characteristics and expression in this study.

Conclusions: was a prognostic factor in glioma, while was not. expression can be a predictor in evaluating the survival outcome of gliomas patients treated with RT+TMZ after surgery.

Citing Articles

Identification of characteristic genes and construction of regulatory network in gallbladder carcinoma.

Shao H, Zhu J, Zhu Y, Liu L, Zhao S, Kang Q BMC Med Genomics. 2023; 16(1):240.

PMID: 37821907 PMC: 10566037. DOI: 10.1186/s12920-023-01663-z.

miR-665 is downregulated in glioma and inhibits tumor cell proliferation, migration and invasion by targeting high mobility group box 1.

Shen H, Xu L, You C, Tang H, Wu H, Zhang Y Oncol Lett. 2021; 21(2):156.

PMID: 33552274 PMC: 7798026. DOI: 10.3892/ol.2020.12417.

miR-137: A Novel Therapeutic Target for Human Glioma.

Wang Y, Chen R, Zhou X, Guo R, Yin J, Li Y Mol Ther Nucleic Acids. 2020; 21:614-622.

PMID: 32736290 PMC: 7393316. DOI: 10.1016/j.omtn.2020.06.028.

Potential Prognostic and Diagnostic Values of CDC6, CDC45, ORC6 and SNHG7 in Colorectal Cancer.

Hu Y, Wang L, Li Z, Wan Z, Shao M, Wu S Onco Targets Ther. 2020; 12:11609-11621.

PMID: 32021241 PMC: 6942537. DOI: 10.2147/OTT.S231941.

Down-regulation of DANCR acts as a potential biomarker for papillary thyroid cancer diagnosis.

Zhang K, Lv J, Peng X, Liu J, Li C, Li J Biosci Rep. 2019; 39(4).

PMID: 30910839 PMC: 6470405. DOI: 10.1042/BSR20181616.

References

Arshad H, Ahmad Z, Hasan S . Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev. 2011; 11(6):1637-40. View

Kreisler A, Strissel P, Strick R, Neumann S, Schumacher U, Becker C . Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer. Oncogene. 2010; 29(43):5828-38. DOI: 10.1038/onc.2010.321. View

Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L . Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004; 64(18):6503-10. DOI: 10.1158/0008-5472.CAN-04-0452. View

Zhang D, Li Y, Wang R, Li Y, Shi P, Kan Z . Inhibition of REST Suppresses Proliferation and Migration in Glioblastoma Cells. Int J Mol Sci. 2016; 17(5). PMC: 4881490. DOI: 10.3390/ijms17050664. View

Sahin S, Gonul I, Cakir A, Seckin S, Uluoglu O . Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer. Int J Surg Pathol. 2016; 24(7):607-13. DOI: 10.1177/1066896916653211. View

Cheng W, Li M, Jiang Y, Zhang C, Cai J, Wang K . Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. J Neurosurg. 2015; 125(1):7-16. DOI: 10.3171/2015.5.JNS142437. View

Lee J, Shimojo M, Chai Y, Hersh L . Studies on the interaction of REST4 with the cholinergic repressor element-1/neuron restrictive silencer element. Brain Res Mol Brain Res. 2000; 80(1):88-98. DOI: 10.1016/s0169-328x(00)00129-7. View

Ren H, Gao Z, Wu N, Zeng L, Tang X, Chen X . Expression of REST4 in human gliomas in vivo and influence of pioglitazone on REST in vitro. Biochem Biophys Res Commun. 2015; 463(4):504-9. DOI: 10.1016/j.bbrc.2015.05.058. View

Murat A, Migliavacca E, Gorlia T, Lambiv W, Shay T, Hamou M . Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008; 26(18):3015-24. DOI: 10.1200/JCO.2007.15.7164. View

10.

Torp S . Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neuropathol. 2002; 21(6):252-7. View

11.

Li C, Wang Z, Tang X, Zeng L, Fan X, Li Z . Molecular mechanisms and potential prognostic effects of REST and REST4 in glioma (Review). Mol Med Rep. 2017; 16(4):3707-3712. DOI: 10.3892/mmr.2017.7071. View

12.

Roopra A, Dingledine R, Hsieh J . Epigenetics and epilepsy. Epilepsia. 2012; 53 Suppl 9:2-10. PMC: 3531878. DOI: 10.1111/epi.12030. View

13.

Lam N, Chambers C . Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation. J Oncol Pharm Pract. 2011; 18(2):229-38. DOI: 10.1177/1078155211426198. View

14.

Taylor P, Fangusaro J, Rajaram V, Goldman S, Helenowski I, MacDonald T . REST is a novel prognostic factor and therapeutic target for medulloblastoma. Mol Cancer Ther. 2012; 11(8):1713-1723. PMC: 3763747. DOI: 10.1158/1535-7163.MCT-11-0990. View

15.

Lambiv W, Vassallo I, Delorenzi M, Shay T, Diserens A, Misra A . The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol. 2011; 13(7):736-47. PMC: 3129269. DOI: 10.1093/neuonc/nor036. View

16.

Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B . Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer. 2013; 49(18):3856-62. PMC: 3853623. DOI: 10.1016/j.ejca.2013.08.006. View

17.

Shimojo M . Characterization of the nuclear targeting signal of REST/NRSF. Neurosci Lett. 2006; 398(3):161-6. DOI: 10.1016/j.neulet.2005.12.080. View

18.

Lee J, Chai Y, Hersh L . Expression patterns of mouse repressor element-1 silencing transcription factor 4 (REST4) and its possible function in neuroblastoma. J Mol Neurosci. 2001; 15(3):205-14. DOI: 10.1385/JMN:15:3:205. View

19.

Li B, Gao Y, Rankin G, Rojanasakul Y, Cutler S, Tu Y . Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells. Cancer Lett. 2014; 356(2 Pt B):418-33. PMC: 4351971. DOI: 10.1016/j.canlet.2014.09.023. View

20.

Hersh L, Shimojo M . Regulation of cholinergic gene expression by the neuron restrictive silencer factor/repressor element-1 silencing transcription factor. Life Sci. 2003; 72(18-19):2021-8. DOI: 10.1016/s0024-3205(03)00065-1. View